ArticleAntimicrobial agents and chemotherapy2019
A 2.5-years within-patient evolution of a
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- L2 β-lactamase contributes to ceftolozane-tazobactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- A novel mechanism of ceftolozane-tazobactam resistance inbioRxiv : the preprint server for biology · 2026Article
- Activity of cefiderocol againstMicrobiology spectrum · 2025Article
- Azithromycin represses evolution of ceftazidime/avibactam resistance by translational repression ofJournal of bacteriology · 2025Article
- Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy.Infectious diseases and therapy · 2025Article
- Ecological and evolutionary mechanisms driving within-patient emergence of antimicrobial resistance.Nature reviews. Microbiology · 2024Review
- Genetic Alternatives for Experimental Adaptation to Colistin in ThreeAntibiotics (Basel, Switzerland) · 2024Article
- Characterization ofAntimicrobial agents and chemotherapy · 2023Article
- Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.Antimicrobial agents and chemotherapy · 2023Article
- Susceptibility profile and β-lactamase content of globalJAC-antimicrobial resistance · 2023Article
- Reversion of Ceftazidime Resistance inMicroorganisms · 2022Article
- Hypermutator strains of Pseudomonas aeruginosa reveal novel pathways of resistance to combinations of cephalosporin antibiotics and beta-lactamase inhibitors.PLoS biology · 2022Article
- Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2022Article
- Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.Microbiology spectrum · 2022Article
- Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.Antimicrobial agents and chemotherapy · 2022Article
- Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2022Article
- Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.Frontiers in cellular and infection microbiology · 2022Observational
- New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.Antimicrobial agents and chemotherapy · 2021Review
- Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis.Nature reviews. Microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftolozane-tazobactam is considered to be a last resort treatment for infections caused by multidrug-resistant (MDR)
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.